Yasuhisa Kimura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yasuhisa Kimura has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
- Kazumitsu Ueda
Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University, Kyoto, Japan
41 shared publications - Noriyuki Kioka
Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Sakyo, Kyoto 606-8502, Japan; Institute for Integrated Cell-Material Sciences (iCeMS), Kyoto University, Sakyo, Kyoto 606-8507, Japan
26 shared publications Michinori Matsuo
Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Kitashirakawa Oiwake-Cho, Sakyo-ku, Kyoto 606-8502, Japan
10 shared publicationsKohjiro Nagao
Department of Synthetic Chemistry and Biological Chemistry, Graduate School of Engineering, Kyoto University, Kyoto, 615-8510, Japan
7 shared publications- Hiroaki Kato
Department of Structural Biology, Graduate School of Pharmaceutical Sciences Kyoto University Kyoto Japan
6 shared publications - Takafumi Ichikawa
Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan
6 shared publications
Latest Publications
- Open Access
- 25 June 2025
- Published by Elsevier in Experimental Cell Research
- Vol. 450 (2) , 114657
Vinculin and c-Cbl-associated protein (CAP) suppress Meflin expression to regulate stiffness-dependent osteogenic differentiation of mesenchymal stem cells
- 25 June 2025
- Published by Elsevier in Experimental Cell Research
- Vol. 450 (2) , 114657
Open AccessVinculin and c-Cbl-associated protein (CAP) suppress Meflin expression to regulate stiffness-dependent osteogenic differentiation of mesenchymal stem cells
- 16 April 2025
- Published by Oxford University Press (OUP) in Bioscience, Biotechnology, and Biochemistry
- Vol. 89 (7) , 990-994
Expression in HEK293 cells, purification, and characterization of recombinant human α-glucosidases
In mammals, intestinal α-glucosidase exists within maltase-glucoamylase (MGAM) and sucrase-isomaltase (SI) complexes. Here, we purified recombinant human MGAM and SI from human embryonic kidney 293 cells using Flag tag-based affinity chromatography. Steady-state kinetic analysis at pH 6.0 and 37 °C showed that the maltase activities of MGAM and SI were higher than their sucrase and isomaltase activities.
- 16 April 2025
- Published by Oxford University Press (OUP) in Bioscience, Biotechnology, and Biochemistry
- Vol. 89 (7) , 990-994
Expression in HEK293 cells, purification, and characterization of recombinant human α-glucosidases
In mammals, intestinal α-glucosidase exists within maltase-glucoamylase (MGAM) and sucrase-isomaltase (SI) complexes. Here, we purified recombinant human MGAM and SI from human embryonic kidney 293 cells using Flag tag-based affinity chromatography. Steady-state kinetic analysis at pH 6.0 and 37 °C showed that the maltase activities of MGAM and SI were higher than their sucrase and isomaltase activities.
- Open Access
- 13 July 2024
- Published by Springer Nature in Communications Chemistry
- Vol. 7 (1) , 1-17
Exploring bat-inspired cyclic tryptophan diketopiperazines as ABCB1 Inhibitors
Chemotherapy-induced drug resistance remains a major cause of cancer recurrence and patient mortality. ATP binding cassette subfamily B member 1 (ABCB1) transporter overexpression in tumors contributes to resistance, yet current ABCB1 inhibitors have been unsuccessful in clinical trials. To address this challenge, we propose a new strategy using tryptophan as a lead molecule for developing ABCB1 inhibitors. Our idea stems from our studies on bat cells, as bats have low cancer incidences and high ABCB1 expression. We hypothesized that potential ABCB1 substrates in bats could act as competitive inhibitors in humans. By molecular simulations of ABCB1-substrate interactions, we generated a benzylated Cyclo-tryptophan (C3N-Dbn-Trp2) that inhibits ABCB1 activity with efficacy comparable to or better than the classical inhibitor, verapamil. C3N-Dbn-Trp2 restored chemotherapy sensitivity in drug-resistant human cancer cells with no adverse effect on cell proliferation. Our unique approach presents a promising lead toward developing effective ABCB1 inhibitors to treat drug-resistant cancers.
- 13 July 2024
- Published by Springer Nature in Communications Chemistry
- Vol. 7 (1) , 1-17
Open AccessExploring bat-inspired cyclic tryptophan diketopiperazines as ABCB1 Inhibitors
Chemotherapy-induced drug resistance remains a major cause of cancer recurrence and patient mortality. ATP binding cassette subfamily B member 1 (ABCB1) transporter overexpression in tumors contributes to resistance, yet current ABCB1 inhibitors have been unsuccessful in clinical trials. To address this challenge, we propose a new strategy using tryptophan as a lead molecule for developing ABCB1 inhibitors. Our idea stems from our studies on bat cells, as bats have low cancer incidences and high ABCB1 expression. We hypothesized that potential ABCB1 substrates in bats could act as competitive inhibitors in humans. By molecular simulations of ABCB1-substrate interactions, we generated a benzylated Cyclo-tryptophan (C3N-Dbn-Trp2) that inhibits ABCB1 activity with efficacy comparable to or better than the classical inhibitor, verapamil. C3N-Dbn-Trp2 restored chemotherapy sensitivity in drug-resistant human cancer cells with no adverse effect on cell proliferation. Our unique approach presents a promising lead toward developing effective ABCB1 inhibitors to treat drug-resistant cancers.
- 12 January 2024
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 175 (6) , 599-609
The ATPase activity of ABCA1 is increased by cholesterol in the presence of anionic lipids
High-density lipoprotein (HDL) transports excess cholesterol from peripheral tissues back to the liver, and plasma HDL levels are inversely related to cardiovascular disease incidence. ATP-binding cassette A1 (ABCA1) is a member of the ABC protein superfamily, and generates nascent HDL, which consists of several hundreds of phospholipids and cholesterol wrapped by apolipoprotein A-I (apoA-I). However, it remains unclear whether cholesterol is a transport substrate of ABCA1. Since ATP hydrolysis of ABC proteins is typically increased by their transport substrates, we characterized the effects of cholesterol on the ATPase activity of purified ABCA1 using liposomes of various lipid compositions. ABCA1 showed substantial ATPase activity (20-30 nmol∙min-1∙mg-1) only in liposomes containing anionic lipids, including phosphatidylserine. Cholesterol increased the ATPase activity by 1.6- to 3-fold in the presence of anionic lipids. Moreover, phosphatidylserine addition to BHK/ABCA1 cells increased phosphatidylcholine and cholesterol efflux to apoA-I. Next, we investigated the sterol specificity of ABCA1. The ATPase activity of ABCA1 was strongly enhanced by desmosterol and zymosterol, similar to cholesterol. In contrast, 7-dehydrocholesterol and lathosterol weakly increased the ATPase activity, and no increase was observed with stigmasterol or brassicasterol. These findings suggest that ABCA1 transports cholesterol, and prefers cholesterol over plant sterols as a transport substrate.
- 12 January 2024
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 175 (6) , 599-609
The ATPase activity of ABCA1 is increased by cholesterol in the presence of anionic lipids
High-density lipoprotein (HDL) transports excess cholesterol from peripheral tissues back to the liver, and plasma HDL levels are inversely related to cardiovascular disease incidence. ATP-binding cassette A1 (ABCA1) is a member of the ABC protein superfamily, and generates nascent HDL, which consists of several hundreds of phospholipids and cholesterol wrapped by apolipoprotein A-I (apoA-I). However, it remains unclear whether cholesterol is a transport substrate of ABCA1. Since ATP hydrolysis of ABC proteins is typically increased by their transport substrates, we characterized the effects of cholesterol on the ATPase activity of purified ABCA1 using liposomes of various lipid compositions. ABCA1 showed substantial ATPase activity (20-30 nmol∙min-1∙mg-1) only in liposomes containing anionic lipids, including phosphatidylserine. Cholesterol increased the ATPase activity by 1.6- to 3-fold in the presence of anionic lipids. Moreover, phosphatidylserine addition to BHK/ABCA1 cells increased phosphatidylcholine and cholesterol efflux to apoA-I. Next, we investigated the sterol specificity of ABCA1. The ATPase activity of ABCA1 was strongly enhanced by desmosterol and zymosterol, similar to cholesterol. In contrast, 7-dehydrocholesterol and lathosterol weakly increased the ATPase activity, and no increase was observed with stigmasterol or brassicasterol. These findings suggest that ABCA1 transports cholesterol, and prefers cholesterol over plant sterols as a transport substrate.
- Open Access
- 1 January 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 296, 100166
ABCA13 dysfunction associated with psychiatric disorders causes impaired cholesterol trafficking
- 1 January 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 296, 100166
Open AccessABCA13 dysfunction associated with psychiatric disorders causes impaired cholesterol trafficking
- Open Access
- 4 December 2020
- Published by Wiley in FEBS Letters
- Vol. 595 (6) , 707-716
ABCB1/MDR1/P‐gp employs an ATP‐dependent twist‐and‐squeeze mechanism to export hydrophobic drugs
ABCB1, also called MDR1 or P‐glycoprotein, exports various hydrophobic compounds and plays an essential role as a protective physiological barrier in several organs, including the brain, testis, and placenta. However, little is known about the structural mechanisms that allow ABCB1 to recognize hydrophobic compounds of diverse structures or the coupling of ATP hydrolysis to uphill substrate export. High‐resolution X‐ray crystal structures of the pre‐ and post‐transport states and FRET analyses in living cells have revealed that an aromatic hydrophobic network at the top of the inner cavity is key for the conformational change in ABCB1 that is triggered by a hydrophobic substrate. ATP binding, but not hydrolysis, induces a progressive network that results in a twisting motion of the whole protein, squeezing out the substrate directly to the extracellular space. This twist‐and‐squeeze mechanism by which ABCB1 exports hydrophobic substrates is distinct from those of other transporters.
- 4 December 2020
- Published by Wiley in FEBS Letters
- Vol. 595 (6) , 707-716
Open AccessABCB1/MDR1/P‐gp employs an ATP‐dependent twist‐and‐squeeze mechanism to export hydrophobic drugs
ABCB1, also called MDR1 or P‐glycoprotein, exports various hydrophobic compounds and plays an essential role as a protective physiological barrier in several organs, including the brain, testis, and placenta. However, little is known about the structural mechanisms that allow ABCB1 to recognize hydrophobic compounds of diverse structures or the coupling of ATP hydrolysis to uphill substrate export. High‐resolution X‐ray crystal structures of the pre‐ and post‐transport states and FRET analyses in living cells have revealed that an aromatic hydrophobic network at the top of the inner cavity is key for the conformational change in ABCB1 that is triggered by a hydrophobic substrate. ATP binding, but not hydrolysis, induces a progressive network that results in a twisting motion of the whole protein, squeezing out the substrate directly to the extracellular space. This twist‐and‐squeeze mechanism by which ABCB1 exports hydrophobic substrates is distinct from those of other transporters.
- 1 November 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 532 (2) , 205-210
Stiffness of the extracellular matrix regulates differentiation into beige adipocytes
- 1 November 2020
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 532 (2) , 205-210
Stiffness of the extracellular matrix regulates differentiation into beige adipocytes
- Open Access
- 1 April 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (15) , 5002-5011
In vivo FRET analyses reveal a role of ATP hydrolysis–associated conformational changes in human P-glycoprotein
- 1 April 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (15) , 5002-5011
Open AccessIn vivo FRET analyses reveal a role of ATP hydrolysis–associated conformational changes in human P-glycoprotein
- 18 June 2019
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (10) , 18406-18414
Estimation of ABCB1 concentration in plasma membrane
The interaction between ABCB1 transporter and its substrates takes place in cell membranes but the available data precludes quantitative analysis of the interaction between transporter and substrate molecules. Further, the amount of transporter is usually expressed as a number of ABCB1 molecules per cell. In contrast, the substrate concentration in cell membranes is estimated by determination of substrate‐lipid partition coefficient, as examples. In this study, we demonstrate an approach, which enables us to estimate the concentration of ABCB1 molecules within plasma membranes. For this purpose, human leukemia K562 cells with varying expression levels of ABCB1 were used: drug selected K562/Dox and K562/HHT cells with very high transporter expression, and K562/DoxDR2, K562/DoxDR1, and K562/DoxDR05 cells with gradually decreased expression of ABCB1 derived from K562/Dox cells using RNA interference technology. First, we determined the absolute amount of ABCB1 in cell lysates using immunoblotting and recombinant ABCB1 as a standard. We then determined the relative portion of transporter residing in the plasma membrane using immunohistochemistry in nonpermeabilized and permeabilized cells. These results enabled us to estimate the concentration of ABCB1 in the plasma membrane in resistant cells. The ABCB1 concentrations in the plasma membrane of drug selected K562/Dox and K562/HHT cells containing the highest amount of transporter reached millimolar levels. Concentrations of ABCB1 in the plasma membrane of resistant K562/DoxDR2, K562/DoxDR1, and K562/DoxDR05 cells with lower transporter expression were proportionally decreased.
- 18 June 2019
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (10) , 18406-18414
Estimation of ABCB1 concentration in plasma membrane
The interaction between ABCB1 transporter and its substrates takes place in cell membranes but the available data precludes quantitative analysis of the interaction between transporter and substrate molecules. Further, the amount of transporter is usually expressed as a number of ABCB1 molecules per cell. In contrast, the substrate concentration in cell membranes is estimated by determination of substrate‐lipid partition coefficient, as examples. In this study, we demonstrate an approach, which enables us to estimate the concentration of ABCB1 molecules within plasma membranes. For this purpose, human leukemia K562 cells with varying expression levels of ABCB1 were used: drug selected K562/Dox and K562/HHT cells with very high transporter expression, and K562/DoxDR2, K562/DoxDR1, and K562/DoxDR05 cells with gradually decreased expression of ABCB1 derived from K562/Dox cells using RNA interference technology. First, we determined the absolute amount of ABCB1 in cell lysates using immunoblotting and recombinant ABCB1 as a standard. We then determined the relative portion of transporter residing in the plasma membrane using immunohistochemistry in nonpermeabilized and permeabilized cells. These results enabled us to estimate the concentration of ABCB1 in the plasma membrane in resistant cells. The ABCB1 concentrations in the plasma membrane of drug selected K562/Dox and K562/HHT cells containing the highest amount of transporter reached millimolar levels. Concentrations of ABCB1 in the plasma membrane of resistant K562/DoxDR2, K562/DoxDR1, and K562/DoxDR05 cells with lower transporter expression were proportionally decreased.
- Open Access
The role of ATP hydrolysis in conformational changes of human P-glycoprotein in living cells
It remains unclear how ATP is used by human P-glycoprotein, a multidrug efflux pump, to extrude various hydrophobic toxic compounds to extracellular space. FRET analysis revealed that binding of two MgATP provides the energy for the conformational change to the rigid outward-facing conformation in living cells. ATP hydrolysis, and subsequent release of γ-phosphate and Mg2+ from both NBDs, allows it to return to the original inward-facing conformation.
Open AccessThe role of ATP hydrolysis in conformational changes of human P-glycoprotein in living cells
It remains unclear how ATP is used by human P-glycoprotein, a multidrug efflux pump, to extrude various hydrophobic toxic compounds to extracellular space. FRET analysis revealed that binding of two MgATP provides the energy for the conformational change to the rigid outward-facing conformation in living cells. ATP hydrolysis, and subsequent release of γ-phosphate and Mg2+ from both NBDs, allows it to return to the original inward-facing conformation.